Cytyc v. TriPath
This article was originally published in The Gray Sheet
Executive Summary
Delaware district court rejects TriPath's motion to file antitrust and unfair competition counterclaims as a part of the ongoing patent suit between the firms. Cytyc filed a suit May 12 in Boston federal court seeking monetary relief and injunction of TriPath's PREP, which allows for the automated preparation of slides to screen for cervical cancer, due to alleged false marketing claims and antitrust issues (1"The Gray Sheet" May 22, p. 9). The ruling notes that TriPath's counterclaims may be appropriate if filed in the Boston court. TriPath plans to pursue its claims that "Cytyc has engaged in predatory and exclusionary anti-competitive conduct," TriPath says in a July 5 release
You may also be interested in...
Cytyc Cites FDA Warning Letter In Second Infringement Action Against TriPath
TriPath's marketing claim that its AutoCyte PREP has results superior and not similar to conventional Pap smear testing "is particularly egregious because it attempts to mislead and confuse consumers about the efficacy and identity of the two products," competitor Cytyc, Inc. claims in a suit filed May 12 in Boston federal court.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.